<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512965</url>
  </required_header>
  <id_info>
    <org_study_id>SC24</org_study_id>
    <nct_id>NCT02512965</nct_id>
  </id_info>
  <brief_title>Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases</brief_title>
  <official_title>A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy(SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients With Spinal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trans Tasman Radiation Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if SBRT is better than CRT at controlling pain in&#xD;
      the spine 3 months after receiving treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done because while there is some evidence suggesting that SBRT may&#xD;
      improve treatment for patients with spine metastases, more research is needed to determine if&#xD;
      it is better than CRT. The first part of the randomized trial (phase II) looked at whether it&#xD;
      was possible (feasible) to provide these treatments in cancer centres across Canada, by&#xD;
      aiming to recruit 54 participants within 18 months. This part of the study was successfully&#xD;
      completed in early 2017. The second component of this study, called a randomized phase III&#xD;
      trial, is now underway. It involves recruiting another 124 participants to receive either CRT&#xD;
      or SBRT, using the same study procedure as in the feasibility study. We will continue to&#xD;
      obtain information about whether SBRT is better than CRT at controlling pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2015</start_date>
  <completion_date type="Actual">August 16, 2021</completion_date>
  <primary_completion_date type="Actual">July 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase III: Complete Pain Response at 3 Months Post-radiation</measure>
    <time_frame>3 months</time_frame>
    <description>A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Pain Response at 6 Months Post Radiation Based on the International Bone Metastases Consensus Working Party Criteria</measure>
    <time_frame>6 months post radiation</time_frame>
    <description>A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Site Progression-free Survival Rate at 6 Months Using MRI Imaging</measure>
    <time_frame>6 months.</time_frame>
    <description>Radiation site progression was defined as:&#xD;
Gross unequivocal increase in tumor volume or linear dimension &gt; 20%.&#xD;
Any new or progressive tumor within the epidural space.&#xD;
Neurologic deterioration attributable to pre-existing epidural disease with equivocal increased epidural disease dimensions on MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate at 6 Months</measure>
    <time_frame>6 months post radiation</time_frame>
    <description>Proportion of participants who were alive at 6 months in study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Spinal Metastases</condition>
  <arm_group>
    <arm_group_label>Standard Conventional Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>20 Gy in 5 fractions</intervention_name>
    <arm_group_label>Standard Conventional Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional SBRT: 24 Gy in 2 fractions</intervention_name>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of cancer (excluding seminoma, small cell lung&#xD;
             cancer and hematologic primaries).&#xD;
&#xD;
          -  Spinal metastasis documented with MRI and suitable for treatment with radiotherapy&#xD;
             with the following characteristics:&#xD;
&#xD;
               -  Painful, as defined by a pain score ≥ 2 for worst pain in the planned target&#xD;
                  treatment volume;&#xD;
&#xD;
               -  ≤ 3 consecutive spinal segments involved by tumour to be included in the planned&#xD;
                  target volume. The patient may have other spinal metaastases to be treated as per&#xD;
                  the radiation oncologist's discretion, but the eligible spinal metastatic site&#xD;
                  has to be one where there is pain and no more than 3 consecutive segments to be&#xD;
                  included as clinical target volume and appropriate for either 20 Gy in 5&#xD;
                  fractions or 24 Gy in 2 fractions per the randomization.&#xD;
&#xD;
          -  There is no plan to change the pain medication on the first day of protocol treatment&#xD;
             with radiotherapy.&#xD;
&#xD;
          -  ECOG Performance Status 0-2.&#xD;
&#xD;
          -  Seen by a radiation oncologist and judged to be appropriate for participation in this&#xD;
             study including ability to tolerate protocol radiotherapy (SBRT or CRT).&#xD;
&#xD;
          -  Age of 18 years or older.&#xD;
&#xD;
          -  Patient is able and willing to complete the Patient Diary (pain and analgesic use).&#xD;
&#xD;
          -  Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life&#xD;
             questionnaire in either English or French. The baseline assessment must be completed&#xD;
             within required timelines, prior to randomization. Inability (illiteracy in English or&#xD;
             French, loss of sight, or other equivalent reason) to complete the questionnaires will&#xD;
             not make the patient ineligible for the study. However, ability but unwillingness to&#xD;
             complete the questionnaires will make the patient ineligible.&#xD;
&#xD;
          -  Patient consent must be appropriately obtained in accordance with applicable local and&#xD;
             regulatory requirements. Each patient must sign a consent form prior to enrollment in&#xD;
             the trial to document their willingness to participate.&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow-up. Investigators must assure&#xD;
             themselves the patients randomized on this trial will be available for complete&#xD;
             documentation of the treatment, adverse events, and follow-up.&#xD;
&#xD;
          -  In accordance with CCTG policy, protocol treatment is to begin within 3 weeks of&#xD;
             patient randomization. From the time of successful treatment planning, no more than 12&#xD;
             days can elapse before the first fraction of radiotherapy is delivered.&#xD;
&#xD;
          -  Women/men of childbearing potential must have agreed to use a highly effective&#xD;
             contraceptive method. A woman is considered to be of &quot;childbearing potential&quot; if she&#xD;
             has had menses at any time in the preceding 12 consecutive months. In addition to&#xD;
             routine contraceptive methods, &quot;effective contraception&quot; also includes heterosexual&#xD;
             celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy&#xD;
             prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal&#xD;
             ligation, or vasectomy/vasectomized partner. However, if at any point a previously&#xD;
             celibate patient chooses to become heterosexually active during the time period for&#xD;
             use of contraceptive measures outlined in the protocol, he/she is responsible for&#xD;
             beginning contraceptive measures.&#xD;
&#xD;
          -  Women of childbearing potential will have a pregnancy test to determine eligibility as&#xD;
             part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy&#xD;
             if a false-positive is suspected. For example, when beta-human chorionic gonadotropin&#xD;
             is high and partner is vasectomized, it may be associated with tumour production of&#xD;
             hCG, as seen with some cancers. Patient will be considered eligible if an ultrasound&#xD;
             is negative for pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have a pacemaker, such that MRI cannot be performed or treatment cannot&#xD;
             be delivered safely.&#xD;
&#xD;
          -  Patients with prior treatment with any radionuclide within 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Patients with prior radiation to the spinal segment intended to be treated with&#xD;
             protocol radiotherapy such that the protocol therapy cannot be delivered as intended.&#xD;
&#xD;
          -  Patients with prior surgery to the spinal segment intended to be treated with protocol&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Patients who have received chemotherapy within 1 week prior to administration of&#xD;
             protocol radiotherapy or who are expected/planned to receive chemotherapy within one&#xD;
             week of completing protocol radiotherapy. Centre guidelines regarding administration&#xD;
             of targeted non-cytotoxic therapy must be followed with the proviso that no systemic&#xD;
             anticancer therapy should be administered within 24 hours prior to and&#xD;
             post-radiotherapy. Endocrine therapy may be administered during radiotherapy as per&#xD;
             the discretion of the treating physician.&#xD;
&#xD;
          -  Patients with spine instability as judged by a Spinal Instability Neoplastic Score&#xD;
             (SINS) of more than 12.&#xD;
&#xD;
          -  Patients with symptomatic spinal cord compression or cauda equina syndrome resulting&#xD;
             from bony compression or epidural compression of the spinal cord and cauda equina,&#xD;
             respectively. Symptomatic refers to neurolic deficit in the form of motor, bowel or&#xD;
             bladder dysfunction.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjun Sahgal</last_name>
    <role>Study Chair</role>
    <affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto ON</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Aucklund</state>
        <zip>1023</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Cancer Therapy Centre, Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter McCallum Cancer Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Mac - Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <zip>ACT 2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Womens Hospital</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Centre for the North</name>
      <address>
        <city>Prince George</city>
        <state>British Columbia</state>
        <zip>V2M 7E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR; trial investigators. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021 Jul;22(7):1023-1033. doi: 10.1016/S1470-2045(21)00196-0. Epub 2021 Jun 11.</citation>
    <PMID>34126044</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>August 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2021</results_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02512965/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02512965/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02512965/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Conventional Radiotherapy</title>
          <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions&#xD;
20 Gy in 5 fractions</description>
        </group>
        <group group_id="P2">
          <title>Stereotactic Body Radiotherapy</title>
          <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions&#xD;
Conventional SBRT: 24 Gy in 2 fractions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="110">4 patients did not receive any dose of the assigned treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Conventional Radiotherapy</title>
          <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions&#xD;
20 Gy in 5 fractions</description>
        </group>
        <group group_id="B2">
          <title>Stereotactic Body Radiotherapy</title>
          <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions&#xD;
Conventional SBRT: 24 Gy in 2 fractions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.05" spread="12.7"/>
                    <measurement group_id="B2" value="63.67" spread="12.1"/>
                    <measurement group_id="B3" value="63.86" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>0: Fully active, able to carry on all pre-disease performance without restriction.&#xD;
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.&#xD;
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Worst pain score</title>
          <description>Pain score range from 0 (no pain) to 10 (pain as bad as you can imagine).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spinal instability neoplastic score (SINS)</title>
          <description>SINS is used to assess the stability of the spine in patients with metastatic spinal cord compression. It ranges from 0 to 18; with 0-6 as stable, 7 - 12 as indeterminate and 13-18 instable.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Radioresistant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiosensitive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mass on imaging</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="115"/>
                    <count group_id="B2" value="114"/>
                    <count group_id="B3" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase III: Complete Pain Response at 3 Months Post-radiation</title>
        <description>A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) .</description>
        <time_frame>3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Conventional Radiotherapy</title>
            <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions&#xD;
20 Gy in 5 fractions</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiotherapy</title>
            <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions&#xD;
Conventional SBRT: 24 Gy in 2 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Phase III: Complete Pain Response at 3 Months Post-radiation</title>
          <description>A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) .</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-evalable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>2-sided, adjusted for stratification factors at randomization.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>6.69</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel estimate stratified by stratification factor at randomization.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Pain Response at 6 Months Post Radiation Based on the International Bone Metastases Consensus Working Party Criteria</title>
        <description>A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) .</description>
        <time_frame>6 months post radiation</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Conventional Radiotherapy</title>
            <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions&#xD;
20 Gy in 5 fractions</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiotherapy</title>
            <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions&#xD;
Conventional SBRT: 24 Gy in 2 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Pain Response at 6 Months Post Radiation Based on the International Bone Metastases Consensus Working Party Criteria</title>
          <description>A Complete Pain Response is defined as a pain score of zero (0) at the treated site with no concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine equivalent) .</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>4.85</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel estimate stratified by stratification factors at randomization.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiation Site Progression-free Survival Rate at 6 Months Using MRI Imaging</title>
        <description>Radiation site progression was defined as:&#xD;
Gross unequivocal increase in tumor volume or linear dimension &gt; 20%.&#xD;
Any new or progressive tumor within the epidural space.&#xD;
Neurologic deterioration attributable to pre-existing epidural disease with equivocal increased epidural disease dimensions on MRI.</description>
        <time_frame>6 months.</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Conventional Radiotherapy</title>
            <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions&#xD;
20 Gy in 5 fractions</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiotherapy</title>
            <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions&#xD;
Conventional SBRT: 24 Gy in 2 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation Site Progression-free Survival Rate at 6 Months Using MRI Imaging</title>
          <description>Radiation site progression was defined as:&#xD;
Gross unequivocal increase in tumor volume or linear dimension &gt; 20%.&#xD;
Any new or progressive tumor within the epidural space.&#xD;
Neurologic deterioration attributable to pre-existing epidural disease with equivocal increased epidural disease dimensions on MRI.</description>
          <population>ITT population</population>
          <units>proportion of participants by arm</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.60" upper_limit="0.77"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.65" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Log Rank</method>
            <method_desc>2-sided p-value adjusted for stratification factors at randomization.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Estimate adjusted for stratification factors at randopmization.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rate at 6 Months</title>
        <description>Proportion of participants who were alive at 6 months in study.</description>
        <time_frame>6 months post radiation</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Conventional Radiotherapy</title>
            <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions&#xD;
20 Gy in 5 fractions</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiotherapy</title>
            <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions&#xD;
Conventional SBRT: 24 Gy in 2 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate at 6 Months</title>
          <description>Proportion of participants who were alive at 6 months in study.</description>
          <population>ITT population.</population>
          <units>proportion of all participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.64" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.68" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <p_value_desc>2-sided p-value adjusted for stratification factors at randomization.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months.</time_frame>
      <desc>Adverse events graded according to CTCAE V4.0&#xD;
In the comments, it says that the number of patients in safety analysis does not agree with the patients flow chart. However, they are indeed different. As 115 and 114 were randomized to CRT and SBRT arm respectively, but there were 4 patients on SBRT arm did not receive any treatment, which leads to the difference. (Safety analyses were based on as-treated population)</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Conventional Radiotherapy</title>
          <description>Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions&#xD;
20 Gy in 5 fractions</description>
        </group>
        <group group_id="E2">
          <title>Stereotactic Body Radiotherapy</title>
          <description>Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions&#xD;
Conventional SBRT: 24 Gy in 2 fractions</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE V4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE V4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Keyue Ding</name_or_title>
      <organization>Canadian Cancer Trials Group</organization>
      <phone>16135336430 ext 77705</phone>
      <email>kding@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

